A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

We have examined the efficacy, toxicity and host immunological response of two different dose schedules of interleukin 2 (IL-2) given subcutaneously, daily for 3 months in patients with renal cell carcinoma (RCC) or metastatic melanoma (MM). We also examined the effect of adding the immune modulator...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ahmed, F. Y., Leonard, G. A., A'Hern, R., Taylor, A. E., Lorentzos, A., Atkinson, H., Moore, J., Nicolson, M. C., Riches, P. G., Gore, M. E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 1996
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2077131/
https://ncbi.nlm.nih.gov/pubmed/8855983
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk